Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann T Farrell

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
The Oncologist|August 18, 2018
FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic MastocytosisYvette L Kasamon, Chia-Wen Ko, Sriram Subramaniam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2017
Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials-ResponsePaul G Kluetz, Elektra J Papadopoulos, Laura Lee Johnson, et al.
JAMA Oncology|March 2, 2018
A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A ReviewJulia A Beaver, Lynn J Howie, Lorraine Pelosof, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2016
Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related SymptomsPaul G Kluetz, Ashley Slagle, Elektra J Papadopoulos, et al.
The Oncologist|September 15, 2017
FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior TherapyVishal Bhatnagar, Nicole J Gormley, Lola Luo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Sorafenib for the treatment of advanced renal cell carcinomaRobert C Kane, Ann T Farrell, Haleh Saber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2021
FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a <i>FLT3</i> MutationE Dianne Pulte, Kelly J Norsworthy, Yaping Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2019
FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid LeukemiaKelly J Norsworthy, Kunthel By, Sriram Subramaniam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2019
FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 MutationKelly J Norsworthy, Lola Luo, Vicky Hsu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2020
Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic AnalysisKelly J Norsworthy, Flora Mulkey, Emma C Scott, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
The Oncologist|August 18, 2018
FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic MastocytosisYvette L Kasamon, Chia-Wen Ko, Sriram Subramaniam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2017
Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials-ResponsePaul G Kluetz, Elektra J Papadopoulos, Laura Lee Johnson, et al.
JAMA Oncology|March 2, 2018
A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A ReviewJulia A Beaver, Lynn J Howie, Lorraine Pelosof, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2016
Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related SymptomsPaul G Kluetz, Ashley Slagle, Elektra J Papadopoulos, et al.
The Oncologist|September 15, 2017
FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior TherapyVishal Bhatnagar, Nicole J Gormley, Lola Luo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Sorafenib for the treatment of advanced renal cell carcinomaRobert C Kane, Ann T Farrell, Haleh Saber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2021
FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a <i>FLT3</i> MutationE Dianne Pulte, Kelly J Norsworthy, Yaping Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2019
FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid LeukemiaKelly J Norsworthy, Kunthel By, Sriram Subramaniam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2019
FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 MutationKelly J Norsworthy, Lola Luo, Vicky Hsu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2020
Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic AnalysisKelly J Norsworthy, Flora Mulkey, Emma C Scott, et al.
Pageof 6